C4 Therapeutics Stock Performance
| CCCC Stock | USD 3.68 0.09 2.51% |
The firm owns a Beta (Systematic Risk) of 1.57, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, C4 Therapeutics will likely underperform. At this point, C4 Therapeutics has a negative expected return of -0.57%. Please make sure to confirm C4 Therapeutics' mean deviation, jensen alpha, potential upside, as well as the relationship between the standard deviation and treynor ratio , to decide if C4 Therapeutics performance from the past will be repeated sooner or later.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days C4 Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of conflicting performance in the last few months, the Stock's fundamental indicators remain rather sound which may send shares a bit higher in March 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return 2.51 | Five Day Return (0.81) | Year To Date Return 0.55 | Ten Year Return (85.56) | All Time Return (85.56) |
1 | Disposition of 12500 shares by Andrew Hirsch of C4 Therapeutics subject to Rule 16b-3 | 11/07/2024 |
2 | C4 Therapeutics, Inc.s 33 percent Share Price Plunge Could Signal Some Risk | 11/15/2024 |
3 | Insider Trading | 11/19/2024 |
4 | Acquisition by Cooper Ronald Harold Wilfred of 65000 shares of C4 Therapeutics at 4.66 subject to Rule 16b-3 | 12/13/2024 |
5 | C4 Therapeutics, Inc. Receives Average Recommendation of Moderate Buy from Analysts - MarketBeat | 12/20/2024 |
6 | Heres Why C4 Therapeutics Is a Great Buy the Bottom Stock Now | 01/02/2025 |
7 | C4 Therapeutics stock plunges to 52-week low of 3.43 - Investing.com | 01/13/2025 |
8 | 3 Penny Stocks On US Exchanges To Consider In January 2025 | 01/16/2025 |
| Begin Period Cash Flow | 33 M |
CCCC |
C4 Therapeutics Relative Risk vs. Return Landscape
If you would invest 561.00 in C4 Therapeutics on November 1, 2024 and sell it today you would lose (193.00) from holding C4 Therapeutics or give up 34.4% of portfolio value over 90 days. C4 Therapeutics is currently does not generate positive expected returns and assumes 5.2734% risk (volatility on return distribution) over the 90 days horizon. In different words, 46% of stocks are less volatile than CCCC, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
C4 Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for C4 Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as C4 Therapeutics, and traders can use it to determine the average amount a C4 Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1073
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CCCC |
Estimated Market Risk
| 5.27 actual daily | 46 54% of assets are more volatile |
Expected Return
| -0.57 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average C4 Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of C4 Therapeutics by adding C4 Therapeutics to a well-diversified portfolio.
C4 Therapeutics Fundamentals Growth
CCCC Stock prices reflect investors' perceptions of the future prospects and financial health of C4 Therapeutics, and C4 Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CCCC Stock performance.
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.21 | ||||
| Operating Margin | (1.84) % | ||||
| Current Valuation | 64.87 M | ||||
| Shares Outstanding | 70.59 M | ||||
| Price To Book | 1.04 X | ||||
| Price To Sales | 7.72 X | ||||
| Revenue | 20.76 M | ||||
| Gross Profit | (74.85 M) | ||||
| EBITDA | (122.1 M) | ||||
| Net Income | (132.49 M) | ||||
| Cash And Equivalents | 307.78 M | ||||
| Cash Per Share | 6.29 X | ||||
| Total Debt | 70.98 M | ||||
| Debt To Equity | 0.25 % | ||||
| Current Ratio | 6.90 X | ||||
| Book Value Per Share | 3.44 X | ||||
| Cash Flow From Operations | (106.84 M) | ||||
| Earnings Per Share | (1.71) X | ||||
| Market Capitalization | 259.77 M | ||||
| Total Asset | 376.45 M | ||||
| Retained Earnings | (528.38 M) | ||||
| Working Capital | 228.42 M | ||||
| Current Asset | 1 K | ||||
| Current Liabilities | 49 K | ||||
About C4 Therapeutics Performance
By analyzing C4 Therapeutics' fundamental ratios, stakeholders can gain valuable insights into C4 Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if C4 Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if C4 Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -3.4 K | -3.2 K | |
| Return On Tangible Assets | (0.40) | (0.42) | |
| Return On Capital Employed | (0.48) | (0.50) | |
| Return On Assets | (0.40) | (0.42) | |
| Return On Equity | (0.62) | (0.59) |
Things to note about C4 Therapeutics performance evaluation
Checking the ongoing alerts about C4 Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for C4 Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| C4 Therapeutics generated a negative expected return over the last 90 days | |
| C4 Therapeutics has high historical volatility and very poor performance | |
| C4 Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 20.76 M. Net Loss for the year was (132.49 M) with loss before overhead, payroll, taxes, and interest of (74.85 M). | |
| C4 Therapeutics currently holds about 307.78 M in cash with (106.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.29, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 92.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from simplywall.st: 3 Penny Stocks On US Exchanges To Consider In January 2025 |
- Analyzing C4 Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether C4 Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining C4 Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating C4 Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of C4 Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of C4 Therapeutics' stock. These opinions can provide insight into C4 Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for CCCC Stock analysis
When running C4 Therapeutics' price analysis, check to measure C4 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy C4 Therapeutics is operating at the current time. Most of C4 Therapeutics' value examination focuses on studying past and present price action to predict the probability of C4 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move C4 Therapeutics' price. Additionally, you may evaluate how the addition of C4 Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |